Hexarelin acetate is a synthetic hexapeptide classified as a potent growth hormone secretagogue (GHS) and ghrelin receptor agonist. Investigated extensively in preclinical and pituitary culture models, it serves as a valuable molecular tool for evaluating somatotrope activation and cardiovascular receptor pathways. PX1 Research supplies laboratory-grade hexarelin acetate backed by lot-specific mass spectrometry, RP-HPLC validation, and endotoxin analysis.
Hexarelin acetate is a synthetic hexapeptide classified as a potent growth hormone secretagogue (GHS) and ghrelin receptor agonist. Investigated extensively in preclinical and pituitary culture models, it serves as a valuable molecular tool for evaluating somatotrope activation and cardiovascular receptor pathways. PX1 Research supplies laboratory-grade hexarelin acetate backed by lot-specific mass spectrometry, RP-HPLC validation, and endotoxin analysis.
Hexarelin acetate is a synthetic hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) engineered as a selective growth hormone secretagogue (GHS) and agonist of the growth hormone secretagogue receptor (GHS-R1a) and scavenger receptor CD36. Studied for ghrelin-receptor activation and growth-hormone secretagogue activity in receptor and pituitary research models, it exhibits high resistance to enzymatic degradation relative to native ghrelin due to the inclusion of D-amino acid substitutions.
Structurally derived from GHRP-6, the amino acid sequence of hexarelin incorporates structural modifications that enhance binding affinity across both pituitary GHS-R1a complexes and cardiac CD36 binding sites. In chemical assays, the acetate salt form provides superior solubility and aqueous reconstitution stability compared to free-base peptide formats. Researchers utilizing hexarelin acetate evaluate its physical properties using high-performance liquid chromatography (HPLC) and electrospray ionization mass spectrometry (ESI-MS) to confirm sequence integrity prior to in vitro binding studies.
Within the broader library of research peptides, hexarelin acetate represents one of the most potent synthetic growth hormone secretagogues tested in preclinical models. Its metabolic stability makes it a key candidate for dissecting intracellular signaling pathways downstream of GHS-R1a engagement, including phospholipase C (PLC) activation, intracellular calcium mobilization, and protein kinase C (PKC) signaling cascades.
The primary mechanism of action for hexarelin acetate revolves around its high-affinity interaction with GHS-R1a, a G-protein-coupled receptor predominantly expressed in the anterior pituitary gland and hypothalamus. Preclinical studies suggest that binding of hexarelin acetate to GHS-R1a triggers the Gq/11 signaling pathway. This stimulates phospholipase C, which catalyzes the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG).
The resulting elevation in intracellular free calcium concentrations induces exocytosis of pre-stored growth hormone granules from pituitary somatotropes. Unlike endogenously produced ghrelin, hexarelin acetate does not require n-octanoylation at its serine residue for bioactivity, permitting simplified synthesized structures for precise in vitro binding assays. Detailed mechanistic analyses can be explored through our comprehensive research hub.
In addition to GHS-R1a activation, hexarelin acetate uniquely exhibits affinity for CD36, a scavenger receptor expressed in cardiac myocytes, endothelial cells, and macrophages. In vitro assays demonstrate that CD36 receptor binding activates intracellular protective pathways independently of growth hormone release, providing researchers with a dual-action ligand for studying both endocrine secretagogue dynamics and localized tissue receptor responses.
In preclinical literature, hexarelin acetate has been documented as inducing robust, dose-dependent growth hormone release in both primary pituitary cell cultures and rodent animal models. Studies comparing pituitary sensitivity across age cohorts indicate that while endogenous growth hormone responsiveness declines with cellular senescence, hexarelin acetate maintains measurable secretagogue potency in isolated aged pituitary tissue.
In vitro data indicate that repeated exposure to hexarelin acetate can lead to GHS-R1a desensitization or receptor down-regulation over extended continuous perfusion protocols. Researchers investigating receptor dynamics utilize pulsatile incubation regimes to study tachyphylaxis kinetics, receptor internalization, and recycling back to the plasma membrane. These experimental designs help define the stoichiometric limits of secretagogue responsiveness in isolated cell models.
Furthermore, preclinical assays evaluating somatotroph interactions reveal that co-incubation of hexarelin acetate with growth hormone-releasing hormone (GHRH) produces a synergistic effect on growth hormone secretion. This synergy indicates that hexarelin acts through distinct intracellular messenger systems independent of the adenylate cyclase/cAMP pathway utilized by canonical GHRH peptides, an area of active investigation in basic endocrine research.
Beyond its role as an endocrine secretagogue, hexarelin acetate occupies a distinct niche in cardiovascular research. Preclinical models of myocardial ischemia-reperfusion injury show that hexarelin acetate exerts direct functional effects on isolated cardiomyocyte cultures and perfused heart preparations (Langendorff heart model). These effects occur independently of systemic growth hormone level alterations, confirming localized tissue receptor interactions.
Investigations indicate that CD36 receptor binding by hexarelin acetate modulates apoptotic pathways in ischemic tissue. In vitro assays using cultured cardiac myocytes demonstrate reduced markers of programmed cell death (such as caspase-3 activation) and decreased reactive oxygen species (ROS) accumulation following hypoxic stress when treated with hexarelin acetate.
Additionally, non-human primate and rodent vascular models suggest hexarelin acetate plays a role in modulating vascular tone and endothelial nitric oxide synthase (eNOS) expression. Researchers studying peripheral microvascular resistance utilize the compound to observe changes in vessel reactivity, endothelial barrier maintenance, and lipid metabolism pathways mediated by macrophage CD36 interaction.
When evaluating synthetic secretagogues, researchers frequently contrast hexarelin acetate with structurally related compounds within the growth hormone-releasing peptide (GHRP) class. A comparative review of GHRP-6, GHRP-2, and ipamorelin reveals critical differences in potency, receptor selectivity, and secondary endocrine activity across in vitro assays.
While GHRP-6 and GHRP-2 demonstrate significant GHS-R1a binding, they also evoke measurable increases in prolactin and cortisol secretion in cultured pituitary assays. In contrast, ipamorelin displays ultra-selective GHS-R1a binding without triggering cortisol or prolactin release, making it a baseline candidate for isolated secretagogue testing. Hexarelin acetate exhibits higher intrinsic secretagogue potency than GHRP-6 and ipamorelin in somatotrope assays, but possesses dual binding affinity for both GHS-R1a and CD36 receptors.
This unique CD36 affinity sets hexarelin acetate apart from pure GHS-R1a agonists, providing a dedicated tool for multi-target research across endocrine and cardiovascular signaling paradigms. For comprehensive procurement options for laboratory studies, consult our wholesale lab account portal or review specialized profiles within our growth hormone secretagogues catalog.
Hexarelin acetate is supplied as a lyophilized, sterile-filtered white powder. To maintain peptide integrity during laboratory experiments, proper reconstitution protocols must be strictly followed. The lyophilized matrix should be allowed to equilibrate to room temperature before opening the vial to prevent ambient moisture condensation within the container.
Reconstitution should be performed using bacteriostatic water (0.9% benzyl alcohol) or sterile deionized water, depending on the requirements of the downstream assay. Solvent should be introduced gently along the glass wall of the vial rather than sprayed directly onto the peptide cake. Gentle swirl mixing is recommended; rigorous agitation or vortexing can disrupt tertiary peptide structure and induce aggregation.
For precise concentration calculations and dilution protocols, researchers should utilize our dedicated peptide reconstitution calculator. Once dissolved, aqueous stock solutions of hexarelin acetate should be aliquoted into single-use polypropylene tubes to minimize freeze-thaw degradation cycles.
Lyophilized hexarelin acetate exhibits high chemical stability when stored at -20°C or -80°C in a desiccated environment, shielded from light exposure. Under these conditions, the peptide remains stable for extended periods without undergoing significant hydrolysis or oxidative cleavage.
Following reconstitution, liquid aliquots should be maintained at 2°C to 8°C for short-term use (up to 7 days) or frozen at -80°C for longer-term storage. Exposure to elevated temperatures, repeated freeze-thaw events, or alkaline pH environments accelerates peptide breakdown, primarily via deamidation of glutamine/asparagine residues or cleavage of peptide bonds.
To prevent contamination and preserve assay reproducibility, researchers must handle all reagents under sterile laminar flow hoods using pyrogen-free laboratory consumables.
Reliable scientific research depends on consistent reagent purity and identity. PX1 Research subjects every batch of hexarelin acetate to a comprehensive suite of analytical tests performed by independent ISO 17025 accredited laboratories. This rigorous quality control process guarantees that researchers receive compounds meeting strict analytical benchmarks.
Purity is verified via reverse-phase high-performance liquid chromatography (RP-HPLC), ensuring a minimum purity threshold of 99%. Identity is unequivocally confirmed through electrospray ionization mass spectrometry (ESI-MS), verifying that the observed molecular weight corresponds precisely to the theoretical mass of hexarelin acetate. Every shipment includes a lot-specific Certificate of Analysis (COA) detailing HPLC chromatograms and mass spectra.
In addition to purity and identity confirmation, PX1 Research measures bacterial endotoxin levels via Chromogenic Reagent Kinetic LAL (Limulus Amebocyte Lysate) testing. Ensuring low endotoxin limits (<0.05 EU/mg) prevents confounding immune receptor activation in sensitive cell cultures and in vitro tissue preparations. All PX1 compounds are manufactured in US-based GMP-compliant facilities.
Procuring standardized, high-purity peptides is critical for ensuring experimental reproducibility across independent trials. PX1 Research serves university laboratories, biotechnology organizations, and academic institutions with domestic US manufacturing and fast, dependable logistics.
All orders ship directly from fulfillment facilities located in California and Arizona, offering same-day dispatch for orders placed Monday through Friday prior to cutoff times. This domestic supply chain minimizes transit duration and eliminates the risks of temperature fluctuations and regulatory delays associated with overseas shipping.
For large-scale screening protocols, multi-phase study designs, or institutional procurement contracts, PX1 Research provides bulk packaging and custom lot-reservation services. Inquire via our institutional purchasing channel to review lot traceability documentation and bulk pricing tiers.
What is the precise chemical definition of hexarelin acetate?
Hexarelin acetate is a synthetic hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, supplied as an acetate salt. It functions as a selective growth hormone secretagogue receptor (GHS-R1a) agonist and CD36 receptor ligand.
Is hexarelin acetate approved for human consumption or medical therapy?
No. Hexarelin acetate is strictly intended for laboratory research use only. It is not approved by the FDA or any regulatory agency for clinical, diagnostic, therapeutic, or human use.
What primary receptor targets are evaluated in hexarelin acetate studies?
Research focuses primarily on the growth hormone secretagogue receptor (GHS-R1a) in pituitary and hypothalamic models, as well as the CD36 scavenger receptor in cardiovascular and endothelial cell assays.
How does hexarelin acetate differ from GHRP-6 and ipamorelin?
Hexarelin acetate exhibits higher secretagogue potency in vitro than GHRP-6 and ipamorelin, and uniquely binds to the CD36 receptor. Unlike ipamorelin, which is ultra-selective for GHS-R1a, hexarelin can induce prolactin and cortisol releases in high-dose pituitary assays.
What purity verification standards does PX1 Research provide for hexarelin acetate?
Every lot undergoes independent ISO 17025 lab testing, including RP-HPLC to verify ≥99% purity, ESI-MS to confirm mass identity, and LAL testing to ensure low endotoxin levels (<0.05 EU/mg). A lot-specific Certificate of Analysis is provided.
How should lyophilized hexarelin acetate be stored upon receipt?
Lyophilized hexarelin acetate should be stored at -20°C or -80°C in a dry, dark environment. Sealed vials remain stable under freezer storage for long-term experimental timelines.
What is the recommended diluent for reconstituting hexarelin acetate for in vitro assays?
Reconstitution is typically performed using sterile laboratory-grade water or bacteriostatic water, depending on assay requirements. Reconstitution guidelines and liquid volume math can be verified using a reconstitution calculator.
Where does PX1 Research manufacture and ship hexarelin acetate from?
PX1 Research products are manufactured in US-based, GMP-compliant facilities and shipped directly from fulfillment centers in California and Arizona with same-day shipping Monday through Friday.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.